Protein phosphatase 2a (PPA2) antagonists for dengue treatment
PPA2 antagonists are used to inhibit PXR activity, effectively reducing dengue virus replication and providing a promising treatment for dengue infections.
WO2025125890A1 Publication Date: 2025-06-19CENTRO DE INVESTIGACION Y DE ESTUDIOS AVANZADOS DEL IPN (CINVESTAV)
1 Cites 0 Cited by
Patent Information
- Application Number
- PCT/IB2023/062834
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-12-16
- Publication Date
- 2025-06-19
AI Technical Summary
Technical Problem
Current treatments for dengue virus infections are inadequate, and there is a need for more effective solutions to inhibit viral replication and reduce the severity of the disease.
Method used
The use of protein phosphatase 2A (PPA2) antagonists to inhibit the activity of Pregnane X Receptor (PXR), which is activated by the dengue virus, thereby suppressing the viral replication and inflammatory response.
Benefits of technology
The administration of PPA2 antagonists significantly reduces the viral load and inhibits the replication of the dengue virus, providing an effective therapeutic approach for treating dengue infections.
✦ Generated by Eureka AI based on patent content.
Abstract
. The invention describes compounds useful for the treatment of viral infection caused by Dengue virus, which comprise compounds that inhibit viral replication of the virus, such as protein phosphatase 2A (PPA2) antagonists, as well as pharmaceutical compositions comprising them, which are useful for the treatment of said viral infection, as well as methods of treatment for viral infection using said compounds and the compositions comprising them.
Need to check novelty before this filing date? Find Prior Art